Yıldız, O.; Aykut, T.; Kaya, B.E.; Genç, Ö.; Gürbüz, A.F.; Saçkan, F.; Eryılmaz, M.K.; Koçak, M.Z.; Araz, M.; Artaç, M.
Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib. Medicina 2025, 61, 1843.
https://doi.org/10.3390/medicina61101843
AMA Style
Yıldız O, Aykut T, Kaya BE, Genç Ö, Gürbüz AF, Saçkan F, Eryılmaz MK, Koçak MZ, Araz M, Artaç M.
Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib. Medicina. 2025; 61(10):1843.
https://doi.org/10.3390/medicina61101843
Chicago/Turabian Style
Yıldız, Oğuzhan, Talat Aykut, Bahattin Engin Kaya, Ömer Genç, Ali Fuat Gürbüz, Fatih Saçkan, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Murat Araz, and Mehmet Artaç.
2025. "Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib" Medicina 61, no. 10: 1843.
https://doi.org/10.3390/medicina61101843
APA Style
Yıldız, O., Aykut, T., Kaya, B. E., Genç, Ö., Gürbüz, A. F., Saçkan, F., Eryılmaz, M. K., Koçak, M. Z., Araz, M., & Artaç, M.
(2025). Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib. Medicina, 61(10), 1843.
https://doi.org/10.3390/medicina61101843
